Hypera S.A. (HYPE3.SA)
- Previous Close
29.01 - Open
0.00 - Bid 28.72 x --
- Ask 28.98 x --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 46.84 - Volume
0 - Avg. Volume
3,210,926 - Market Cap (intraday)
18.219B - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
11.11 - EPS (TTM)
2.59 - Earnings Date Apr 26, 2024
- Forward Dividend & Yield 1.22 (4.18%)
- Ex-Dividend Date Apr 24, 2024
- 1y Target Est
42.96
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.
www.hyperapharma.com.br10,301
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: HYPE3.SA
Performance Overview: HYPE3.SA
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HYPE3.SA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HYPE3.SA
Valuation Measures
Market Cap
18.42B
Enterprise Value
25.80B
Trailing P/E
11.25
Forward P/E
10.07
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.34
Price/Book (mrq)
1.60
Enterprise Value/Revenue
3.26
Enterprise Value/EBITDA
8.97
Financial Highlights
Profitability and Income Statement
Profit Margin
20.82%
Return on Assets (ttm)
6.48%
Return on Equity (ttm)
14.89%
Revenue (ttm)
7.91B
Net Income Avi to Common (ttm)
1.65B
Diluted EPS (ttm)
2.59
Balance Sheet and Cash Flow
Total Cash (mrq)
2.58B
Total Debt/Equity (mrq)
88.38%
Levered Free Cash Flow (ttm)
40.85M
Research Analysis: HYPE3.SA
Company Insights: HYPE3.SA
HYPE3.SA does not have Company Insights